Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Responses to glycemic control therapy according to age, gender, level of adiposity, and duration of diabetes in type 2 diabetic patients.

Ewenighi CO, Uchechukwu D, Adejumo BI, Onyeanusi JC, Nnatuanya IN, Onoh OG, Okorie CE, Ogbuike OI.

Indian J Med Sci. 2013 Mar-Apr;67(3-4):61-9. doi: 10.4103/0019-5359.121117.

PMID:
24231394
2.

Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.

Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ.

J Acad Nutr Diet. 2015 Sep;115(9):1447-63. doi: 10.1016/j.jand.2015.02.031. Epub 2015 Apr 29. Review.

PMID:
25935570
3.

Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial.

Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, Gicchino M, Petrizzo M, Saccomanno F, Beneduce F, Ceriello A, Giugliano D.

Ann Intern Med. 2009 Sep 1;151(5):306-14. Erratum in: Ann Intern Med. 2009 Oct 20;151(8):591.

PMID:
19721018
4.

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

Fritsche A, Schmülling RM, Häring HU, Stumvoll M.

Acta Diabetol. 2000 Mar;37(1):13-8.

PMID:
10928231
5.
6.
7.

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P.

Diabetes Care. 2002 Jun;25(6):1033-41. Erratum in: Diabetes Care. 2003 Mar;26(3):971..

PMID:
12032111
10.

Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study.

Vichayanrat A, Matawaran BJ, Wibudi A, Ferdous HS, Aamir AH, Aggarwal SK, Bajpai S.

J Diabetes. 2013 Sep;5(3):309-18. doi: 10.1111/1753-0407.12038. Epub 2013 May 28.

PMID:
23462227
11.

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.

Jacob S, Rabbia M, Meier MK, Hauptman J.

Diabetes Obes Metab. 2009 Apr;11(4):361-71. doi: 10.1111/j.1463-1326.2008.00970.x. Epub 2009 Jan 22.

PMID:
19207292
13.

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.

Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.

Clin Ther. 2004 Sep;26(9):1427-35.

PMID:
15531005
14.

Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.

Shi YF, Pan CY, Hill J, Gao Y.

Diabet Med. 2005 Dec;22(12):1737-43.

PMID:
16401321
16.

The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.

Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER.

Diabet Med. 2006 Feb;23(2):128-33.

PMID:
16433709
17.

Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.

Vinik AI, Cincotta AH, Scranton RE, Bohannon N, Ezrokhi M, Gaziano JM.

Endocr Pract. 2012 Nov-Dec;18(6):931-43. doi: 10.4158/EP12187.OR. Erratum in: Endocr Pract. 2013 Jan-Feb;19(1):179.

PMID:
23186965
18.

Slow response to loss of glycemic control in type 2 diabetes mellitus.

Brown JB, Nichols GA.

Am J Manag Care. 2003 Mar;9(3):213-7.

19.

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.

Jones TA, Sautter M, Van Gaal LF, Jones NP.

Diabetes Obes Metab. 2003 May;5(3):163-70.

PMID:
12681023

Supplemental Content

Support Center